Compare CDP & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | STVN |
|---|---|---|
| Founded | 1988 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Containers/Packaging |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 1996 | 2021 |
| Metric | CDP | STVN |
|---|---|---|
| Price | $30.76 | $18.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $34.57 | $25.67 |
| AVG Volume (30 Days) | ★ 821.0K | 563.7K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.14% | 0.39% |
| EPS Growth | ★ 8.94 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $763,923,000.00 | N/A |
| Revenue This Year | $1.18 | $9.67 |
| Revenue Next Year | $3.71 | $9.99 |
| P/E Ratio | ★ $22.86 | $27.15 |
| Revenue Growth | ★ 1.41 | N/A |
| 52 Week Low | $26.37 | $12.89 |
| 52 Week High | $33.29 | $28.00 |
| Indicator | CDP | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.37 | 77.92 |
| Support Level | $30.35 | $13.58 |
| Resistance Level | $31.04 | $26.94 |
| Average True Range (ATR) | 0.66 | 0.79 |
| MACD | -0.18 | 0.31 |
| Stochastic Oscillator | 11.31 | 99.03 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.